

## *Curriculum vitae*

NAME CHU-AN WANG	POSITION TITLE Postdoctoral Fellow, National Cheng Kung University, Tainan, Taiwan		
EDUCATION/TRAINING			
INSTITUTION AND LOCATION	DEGREE	YEAR(s)	FIELD OF STUDY
Chung Shan Medical University, Taichung, Taiwan	B.S.	1998-2002	Life Science
National Cheng Kung University, Tainan, Taiwan	M.S.	2002-2004	Molecular Medicine
University of Colorado Denver, Anschutz Medical Campus	Ph.D.	2007-2012	Molecular Biology
University of Colorado Denver, Anschutz Medical Campus	Postdoc fellow	2012-2014	Pharmacology
National Cheng Kung University, Tainan, Taiwan	Postdoc fellow	2014-present	Basic Medical Science

### PROFESSIONAL POSITIONS:

- 1998-2002 **college student**- Chung Shan Medical University, Taichung, Taiwan  
Department of Life Science  
2000 -Summer student, Dr. H. Lee's Laboratory, Institute of medical and Molecular Toxicology, Chung Shan Medical University, Taichung, Taiwan
- 2002-2004 **master student**- National Cheng Kung University, Tainan, Taiwan  
Department of Molecular Medicine  
Thesis: Distinct mechanism of Interleukine-1 $\beta$ -induced cyclooxygenase-2 expression in endometriotic stromal cell  
Mentor: Shaw-Jenq Tsai, Ph.D.
- 2006-2007 **research assistant**- National Cheng Kung University, Tainan, Taiwan  
Department of Urology
- 2007-2012 **graduate student**-University of Colorado Denver, Anschutz Medical Campus  
Aug Program of Molecular biology  
Thesis: Thesis: Cell and non-cell autonomous functions of the SIX1 and SIX2 homeoproteins and growth factor VEGF-C in breast cancer progression  
Mentor: Heide L. Ford, Ph.D.
- 2012-2014 **postdoctoral fellow**- University of Colorado Denver, Anschutz Medical Campus  
Oct Jun Department of Pharmacology  
Mentor: Heide L. Ford, Ph.D.
- 2014 Aug **postdoctoral fellow**- National Cheng Kung University, Tainan, Taiwan  
-present Institute of Basic Medical Sciences  
Mentor: Shaw-Jenq Tsai, Ph.D.

## SCIENTIFIC MEETINGS:

2003-9th Taiwan-Hong Kong Physiology Symposium in the University Of Hong Kong, Hong Kong (poster)  
2003-19th Conference of the Taiwan Society Biochemistry and Molecular Biology, Taipei, Taiwan (poster)  
2004-37th Annual meetings of Society for the Study of Reproduction, Vancouver, Canada (oral presentation)  
2006-16th Biennial congress of the world council of enterostomal therapists, Hong Kong (poster)  
2009-AACR 100th annual meeting, Denver, Colorado (poster)  
2010- Joint MRS-AACR Conference on Metastasis and the Tumor Microenvironment, Philadelphia, Pennsylvania, September 12-15, 2010 (poster)  
2011-102nd AACR Annual Meeting 2011 in Orlando, Florida, April 2-6, 2011 (poster)  
2011-Department of Defense Era of Hope Meeting, Orlando, Florida, August 2-5, 2011 (poster)  
2013- AACR Annual Meeting 2013 Washington, DC, April 6-10 (poster)-featured by AACR news release of the University of Colorado Cancer Center  
2013- AACR Advances in Breast Cancer Research, San Diego, CA, October 3-6, 2013-invited talk at Session 4: Tumor Dormancy and Metastasis

## MEMBERSHIPS IN PROFESSIONAL SOCIETIES

2004-2005 Society For The Study Of Reproduction  
2009-present American Association for Cancer Research, Associate member  
2009-present Women in Cancer Research (AACR)

## PUBLICATIONS:

1. Meng-Hsing Wu,\* **Chu-An Wang**,\* Chen-Chung Lin, Lei-Chin Chen, Wen-Chang Chang, and Shaw-Jenq Tsai. Distinct regulation of cyclooxygenase-2 by interleukin-1beta in normal and endometriotic stromal cells. *J Clin Endocrinol Metab.* 2005 Jan;90(1):286-95.
  2. W. Chen,S.-J. Tsai, **C.-A. Wang**, J.-C. Tsai, C.C. Zouboulis. Human sebocytes express prostaglandin E2 receptors EP2 and EP4 but treatment with prostaglandin E2 does not affect testosterone production. *Br J Dermatol.* 2009 Sep;161(3):674-7.
  3. Micalizzi DS, **Wang CA**, Farabaugh SM, Schiemann WP, Ford HL. Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth. *Cancer Res.* 2010 Dec 15;70(24):10371-80.
  4. **Wang CA**, Jedlicka P, Patrick AN, Micalizzi DS, Lemmer KC, Deitsch E, Casás-Selves M, Harrell JC, Ford HL. SIX1 induces lymphangiogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer. *J Clin Invest.* 2012 May 1;122(5):1895-906.  
Research was highlighted as a short article at: Metastasis: SIX1 of the best. *Nat Rev Cancer.* 2012 May 24;12(5):316.
  5. Ritsuko Iwanaga, **Chu-An Wang**, Douglas S. Micalizzi, Chuck J. Harrell, Paul Jedlicka, Carol Sartorius, Peter Kabos, Andrew P Bradford, Heide L. Ford. Six1 enhances tumor initiating cell activity and predicts poor prognosis in luminal breast cancers. *Breast Cancer Res.* 2012 Jul 5;14(4):R100.
  6. **Wang CA**, Harrell J, Iwanaga R, Jedlicka P, Ford HL. Vascular endothelial growth factor-C promotes breast cancer progression via a novel anti-oxidant mechanism that involves regulation of Superoxide dismutase 3. *Breast Cancer Res.* 2014 Oct 30;16(5):462.
  7. **Wang CA**, Drasin DJ, Pham C, Jedlicka P, Zaberezhnyy V, Guney M, Li H, Nemenoff R, Costello J, Tan AC, Ford HL. Homeoprotein Six2 Promotes Breast Cancer Metastasis via Transcriptional and Epigenetic Control of E-Cadherin Expression. *Cancer Res.* 2014 Dec 15;74(24):7357-70.
  8. David J. Drasin , Anna L. Guarnieri , Deepika Neelakantan , Jihye Kim , Joshua H. Cabrera , **Chu-An Wang** , Vadym Zaberezhnyy , Pierluigi Gasparini , Luciano Cascione , Kay Huebner , Aik Choon Tan, Ford HL.
-

TWIST1-induced microRNA-424 reversibly drives mesenchymal programming while inhibiting tumor initiation. *Cancer Res.* 2015 Feb 25.

9. **Wang CA** and Shaw-Jenq Tsai. The non-canonical role of vascular endothelial growth factor-C axis in cancer progression. *Experimental Biology and Medicine.* 2015 Apr 16.
10. Towers CG, Guarnieri AL, Micalizzi DS, Harrell JC, Gillen AE, Kim J, **Wang CA**, Oliphant MU, Drasin DJ, Guney MA, Kabos P, Sartorius CA, Tan AC, Perou CM, Espinosa JM, Ford HL. The Six1 oncoprotein represses translation of p53 via concomitant regulation of RPL26 and microRNA-27a. *Nat Commun.* 2015 Dec 21;6:10077.

#### **AWARDS & GRANTS:**

1. 01/01/2010-12/31/2012- predoctoral fellowship award to CA Wang from the Department of Defense Breast Cancer Research Program (W81ZWH-10-1-0162). Project title: *Six 1 Regulated VEGF-C, Lymphangiogenesis, and Lymphatic Breast Cancer Metastasis.*
  2. 2013-AACR-Aflac, Incorporated Scholar-in-Training Awards, 2013 AACR Advances in Breast Cancer Research
  3. 07/01/2013-06/30/2014- research grant awarded to CA Wang from the Cancer League of Colorado. Project title: *Targeting vascular endothelial growth factor C in the cancer-stem like population sensitizes breast cancer cells to oxidative stress and inhibits tumor progression.*
  4. 08/01/2014-07/31/2017-Independent postdoctoral grant awarded to CA Wang from Ministry of Sciences and Technology (103-2321-B-006-020-MY3).
-